

Peripheral Arterial Disease (PAD) Therapeutics-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/P6091835721MEN.html

Date: March 2018

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: P6091835721MEN

Abstracts

Report Summary

Peripheral Arterial Disease (PAD) Therapeutics-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Peripheral Arterial Disease (PAD) Therapeutics industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Peripheral Arterial Disease (PAD) Therapeutics 2013-2017, and development forecast 2018-2023

Main market players of Peripheral Arterial Disease (PAD) Therapeutics in EMEA, with company and product introduction, position in the Peripheral Arterial Disease (PAD) Therapeutics market

Market status and development trend of Peripheral Arterial Disease (PAD) Therapeutics by types and applications

Cost and profit status of Peripheral Arterial Disease (PAD) Therapeutics, and marketing status

Market growth drivers and challenges

The report segments the EMEA Peripheral Arterial Disease (PAD) Therapeutics market as:

EMEA Peripheral Arterial Disease (PAD) Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):



Europe

Middle East

Africa

EMEA Peripheral Arterial Disease (PAD) Therapeutics Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others

EMEA Peripheral Arterial Disease (PAD) Therapeutics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Clinics

Others

EMEA Peripheral Arterial Disease (PAD) Therapeutics Market: Players Segment Analysis (Company and Product introduction, Peripheral Arterial Disease (PAD) Therapeutics Sales Volume, Revenue, Price and Gross Margin):

AstraZeneca Plc. (UK)

Bayer HealthCare Pharmaceuticals (Germany)

Bristol-Myers Squibb Company (US)

Merck & Co., Inc. (US)

Proteon Therapeutics, Inc. (US)

Sanofi S.A. (France)

Symic Bio, Inc. (US)

TheraVasc Inc. (US)

AnGes MG, Inc. (Japan)

Athersys, Inc. (US)

Betagenon AB (Sweden)

miRagen Therapeutics, Inc. (US)

Multi Gene Vascular Systems Ltd (Israel)

ViroMed Co. Ltd. (Korea)

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF PERIPHERAL ARTERIAL DISEASE (PAD) THERAPEUTICS

- 1.1 Definition of Peripheral Arterial Disease (PAD) Therapeutics in This Report
- 1.2 Commercial Types of Peripheral Arterial Disease (PAD) Therapeutics
 - 1.2.1 Anti-Platelet Drugs
 - 1.2.2 Dual Antiplatelet Therapy Drugs
 - 1.2.3 Others
- 1.3 Downstream Application of Peripheral Arterial Disease (PAD) Therapeutics
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Others
- 1.4 Development History of Peripheral Arterial Disease (PAD) Therapeutics
- 1.5 Market Status and Trend of Peripheral Arterial Disease (PAD) Therapeutics 2013-2023
- 1.5.1 EMEA Peripheral Arterial Disease (PAD) Therapeutics Market Status and Trend 2013-2023
- 1.5.2 Regional Peripheral Arterial Disease (PAD) Therapeutics Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Peripheral Arterial Disease (PAD) Therapeutics in EMEA 2013-2017
- 2.2 Consumption Market of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Regions
- 2.2.1 Consumption Volume of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Regions
- 2.2.2 Revenue of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Regions
- 2.3 Market Analysis of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Regions
- 2.3.1 Market Analysis of Peripheral Arterial Disease (PAD) Therapeutics in Europe 2013-2017
- 2.3.2 Market Analysis of Peripheral Arterial Disease (PAD) Therapeutics in Middle East 2013-2017
- 2.3.3 Market Analysis of Peripheral Arterial Disease (PAD) Therapeutics in Africa 2013-2017



- 2.4 Market Development Forecast of Peripheral Arterial Disease (PAD) Therapeutics in EMEA 2018-2023
- 2.4.1 Market Development Forecast of Peripheral Arterial Disease (PAD) Therapeutics in EMEA 2018-2023
- 2.4.2 Market Development Forecast of Peripheral Arterial Disease (PAD) Therapeutics by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
- 3.1.1 Consumption Volume of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Types
- 3.1.2 Revenue of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Downstream Industry
- 4.2 Demand Volume of Peripheral Arterial Disease (PAD) Therapeutics by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Peripheral Arterial Disease (PAD) Therapeutics by Downstream Industry in Europe
- 4.2.2 Demand Volume of Peripheral Arterial Disease (PAD) Therapeutics by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Peripheral Arterial Disease (PAD) Therapeutics by Downstream Industry in Africa
- 4.3 Market Forecast of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) THERAPEUTICS



- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Peripheral Arterial Disease (PAD) Therapeutics Downstream Industry Situation and Trend Overview

CHAPTER 6 PERIPHERAL ARTERIAL DISEASE (PAD) THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Major Players
- 6.2 Revenue of Peripheral Arterial Disease (PAD) Therapeutics in EMEA by Major Players
- 6.3 Basic Information of Peripheral Arterial Disease (PAD) Therapeutics by Major Players
- 6.3.1 Headquarters Location and Established Time of Peripheral Arterial Disease (PAD) Therapeutics Major Players
- 6.3.2 Employees and Revenue Level of Peripheral Arterial Disease (PAD) Therapeutics Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 PERIPHERAL ARTERIAL DISEASE (PAD) THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 AstraZeneca Plc. (UK)
 - 7.1.1 Company profile
 - 7.1.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.1.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca Plc. (UK)
- 7.2 Bayer HealthCare Pharmaceuticals (Germany)
 - 7.2.1 Company profile
 - 7.2.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.2.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of Bayer HealthCare Pharmaceuticals (Germany)
- 7.3 Bristol-Myers Squibb Company (US)
 - 7.3.1 Company profile
 - 7.3.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
 - 7.3.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and



Gross Margin of Bristol-Myers Squibb Company (US)

- 7.4 Merck & Co., Inc. (US)
 - 7.4.1 Company profile
 - 7.4.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.4.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. (US)
- 7.5 Proteon Therapeutics, Inc. (US)
 - 7.5.1 Company profile
 - 7.5.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.5.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of Proteon Therapeutics, Inc. (US)
- 7.6 Sanofi S.A. (France)
 - 7.6.1 Company profile
 - 7.6.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.6.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of Sanofi S.A. (France)
- 7.7 Symic Bio, Inc. (US)
 - 7.7.1 Company profile
 - 7.7.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.7.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of Symic Bio, Inc. (US)
- 7.8 TheraVasc Inc. (US)
 - 7.8.1 Company profile
 - 7.8.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.8.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of TheraVasc Inc. (US)
- 7.9 AnGes MG, Inc. (Japan)
 - 7.9.1 Company profile
 - 7.9.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.9.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of AnGes MG, Inc. (Japan)
- 7.10 Athersys, Inc. (US)
 - 7.10.1 Company profile
 - 7.10.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.10.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of Athersys, Inc. (US)
- 7.11 Betagenon AB (Sweden)
 - 7.11.1 Company profile
- 7.11.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product



- 7.11.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of Betagenon AB (Sweden)
- 7.12 miRagen Therapeutics, Inc. (US)
 - 7.12.1 Company profile
- 7.12.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.12.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of miRagen Therapeutics, Inc. (US)
- 7.13 Multi Gene Vascular Systems Ltd (Israel)
 - 7.13.1 Company profile
- 7.13.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.13.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of Multi Gene Vascular Systems Ltd (Israel)
- 7.14 ViroMed Co. Ltd. (Korea)
 - 7.14.1 Company profile
 - 7.14.2 Representative Peripheral Arterial Disease (PAD) Therapeutics Product
- 7.14.3 Peripheral Arterial Disease (PAD) Therapeutics Sales, Revenue, Price and Gross Margin of ViroMed Co. Ltd. (Korea)

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) THERAPEUTICS

- 8.1 Industry Chain of Peripheral Arterial Disease (PAD) Therapeutics
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) THERAPEUTICS

- 9.1 Cost Structure Analysis of Peripheral Arterial Disease (PAD) Therapeutics
- 9.2 Raw Materials Cost Analysis of Peripheral Arterial Disease (PAD) Therapeutics
- 9.3 Labor Cost Analysis of Peripheral Arterial Disease (PAD) Therapeutics
- 9.4 Manufacturing Expenses Analysis of Peripheral Arterial Disease (PAD) Therapeutics

CHAPTER 10 MARKETING STATUS ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) THERAPEUTICS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing



- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Peripheral Arterial Disease (PAD) Therapeutics-EMEA Market Status and Trend Report

2013-2023

Product link: https://marketpublishers.com/r/P6091835721MEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P6091835721MEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



